Abstract: The present invention relates to the identification of novel panels and combinations of biomarkers for ovarian cancer. An in vitro method is provided for detecting, predicting or monitoring ovarian cancer in a subject, wherein said method comprises determining in a sample from said subject the levels of the biomarkers in a panel comprising: TACSTD2, PROK1, MSMB, MUC-16, WFDC2, FR-alpha, and KRT19. More broadly, biomarkers may be selected and used from this list in variations combinations with each other and with other biomarkers. Also provided are sets of reagents for use in such methods.